These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38368200)

  • 41. [Cardioprotective effects of glucagon-like peptide 1 receptor agonists].
    Ametov AS; Kamynina LL; Akhmedova ZG
    Kardiologiia; 2014; 54(7):92-6. PubMed ID: 25177820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical use of GLP-1 agonists and DPP4 inhibitors.
    Tuch BE
    Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glucagon-like peptide analogues for type 2 diabetes mellitus.
    Shyangdan DS; Royle P; Clar C; Sharma P; Waugh N; Snaith A
    Cochrane Database Syst Rev; 2011 Oct; 2011(10):CD006423. PubMed ID: 21975753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incretin therapy for diabetes mellitus type 2.
    Holst JJ
    Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):2-10. PubMed ID: 31815785
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Care of type 2 diabetes: where do the new medications fit?
    Clem CO; Heins JR
    S D Med; 2015 Mar; 68(3):126-7. PubMed ID: 25906502
    [No Abstract]   [Full Text] [Related]  

  • 47. Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity.
    Li Q; Yang Q; Han J; Liu X; Fu J; Yin J
    Chin J Nat Med; 2022 Nov; 20(11):863-872. PubMed ID: 36427920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
    Scheen AJ
    Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relevance of beta-cell function for improved glycemic control after gastric bypass surgery.
    Blanco J; Jiménez A; Casamitjana R; Flores L; Lacy A; Conget I; Vidal J
    Surg Obes Relat Dis; 2014; 10(1):9-13; quiz 189-90. PubMed ID: 24342036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment.
    Mahase E
    BMJ; 2024 Jul; 386():q1645. PubMed ID: 39043396
    [No Abstract]   [Full Text] [Related]  

  • 52. Exenatide for the treatment of type 2 diabetes mellitus.
    Ruddock B
    Issues Emerg Health Technol; 2005 Aug; (71):1-4. PubMed ID: 16389694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
    Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
    Okerson T; Yan P; Stonehouse A; Brodows R
    Am J Hypertens; 2010 Mar; 23(3):334-9. PubMed ID: 20019672
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
    Gong B; Yao Z; Zhou C; Wang W; Sun L; Han J
    Eur J Med Chem; 2024 Apr; 269():116342. PubMed ID: 38531211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
    Nauck MA; Meier JJ
    Nat Rev Endocrinol; 2011 Apr; 7(4):193-5. PubMed ID: 21326278
    [No Abstract]   [Full Text] [Related]  

  • 58. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetes: Concerns about long-term use of GLP-1 analogues.
    Holmes D
    Nat Rev Endocrinol; 2016 Apr; 12(4):186. PubMed ID: 26939977
    [No Abstract]   [Full Text] [Related]  

  • 60. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.